Effects of food on the pharmacokinetics of ponatinib in healthy subjects

WHAT IS KNOWN AND OBJECTIVE: Ponatinib is a potent oral tyrosine kinase inhibitor with activity against BCR-ABL, the primary driver of chronic myeloid leukaemia and Philadelphia chromosome–positive acute lymphoblastic leukaemia. This single-centre, single-dose, randomized, open-label, three-period c...

Descripción completa

Detalles Bibliográficos
Autores principales: Narasimhan, NI, Dorer, DJ, Niland, K, Haluska, F, Sonnichsen, Daryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286001/
https://www.ncbi.nlm.nih.gov/pubmed/23888935
http://dx.doi.org/10.1111/jcpt.12082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286001/
https://www.ncbi.nlm.nih.gov/pubmed/23888935
http://dx.doi.org/10.1111/jcpt.12082

Ejemplares similares